​

•  Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study. Diabetes Obes Metab. 2026 ici

• Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial. FrontEndocrinol 2025 Dec 19: 16: 1716587 ici 

• Body weight trends in Individuals with type 1 diabetes using automated insulin delivery vs. traditional insulin pumps. Diabetes & Metabolism 2025; 51: 101693 ici.

• Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People with Type 1 Diabetes in France. Diabetes Technol Thera 2025 ici

• La boucle fermée hybride : évolution ou révolution dans la prise en charge du diabète de type 1, Bull Acad Natl Med 2025 ici

• Screening and care for preclinical stage 1-2 type 1 diabetes in first-degree relatives: French expert position statement. Diabetes & Metabolism 2024  ici

• Advanced Hybrid Closed Loop Algorithm Use in Type 1 Diabetes: The French MiniMed™ Glycemic Control and Quality of Life Study. Diabetes Ther 2024  ici

• Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical Trial. Diabetes Care 2024  ici

• Ascertaining the utility of the Glycemia Risk Index for glucose outcomes With Hybrid Closed-Loop Therapy in Adolescents and Adults With Type 1 Diabetes. J diab sci Technol 2024   ici

• Impacts des évolutions technologiques sur la gestion des repas au cours du diabète de type 1. Médecine Maladies Métaboliques 2024   ici

• Hope, hype and present limitations of hybrid closed loop systems for persons with type 1 diabetes. Diabetes & Metabolism 2024  ici

• Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Diabetes Obes Metab. 2024 ici

• Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes. Diabetes Obes Metabol 2023 ici

• Real world evidence of the efficacy of two Hybrid closed loop systems for children and adults with type 1 diabetes with some clinical warnings. Diabetes & Metabolism 2022 ici

• Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study, Lancet Diabetes Endocrinol 2022 ici

• Hybrid closed Loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring, Acta Diabetologica 2021  ici

• Insulin pump initiation in outpatient settings: when technology facilitates new healthcare organizations. Diabetes & Metabolism 2021  ici

• Pumps that predict and manage low blood glucose are superior to pumps with stand-alone CGM for reducing hypoglycaemia in type 1 diabetes patients in a real-world setting Diabetes & Metabolism 2021  ici

• Effects of remote care of patients with poorly controlled type 1 diabetes included in an experimental telemonitoring programme. Diabetes & Metabolism 2021  ici

• Histoire naturelle des cellules bêta au cours du diabète de type 1 : conséquences cliniques et possibilités thérapeutiques.  Médecine Maladies Métaboliques 2020.  ici

​

• Protéger sa peau avec un diabète. Livret DIAB-eCARE productions.  ici

​

​

​

​